BTG Share News (BTG)

BTG Information

There is currently no data for BTG

BTG's emphysema treatment struck down by FDA

Thu, 09th Aug 2018 09:04

(Sharecast News) - Global specialist healthcare company BTG on Thursday received confirmation from the US food and drug administration (FDA) that its emphysema treatment will not receive pre-market approval.The company's Elevair Endobronchial Coil System, which was designed to treat patients suffering severe symptoms, had previously failed to receive backing from the FDA's anaesthesiology and respiratory therapy devices panel of the medical devices advisory committee in June.The company had initially reacted by committing to generating clinical data to support its assessment that had "a role to play" in the management of patients with severe emphysema who had few treatment options.But analysts at Peel Hunt said that investors had likely already written off the London-listed company's product for the US market on account of the earlier failing."As such this news will have little impact on estimates or valuation, but might be a small incremental negative for sentiment as it reinforces the difficulty BTG is experiencing in its attempt to pivot the group to interventional medicine amid the decline of its other two more legacy divisions," Peel said.The coils, which are known as PneumRX Coils in Europe, are designed to be permanently implanted in the most emphysema-damaged parts of the lung to allow more efficient contraction that helps assist the breathing cycle.BTG shares were down 1.90% to 515.00p at 0828 BST.

More News

8 Jun 2016 13:18

Wednesday broker round-up

(ShareCast News) - Hochschild Mining: UBS downgrades to neutral with a target price of 160p. Esure Group: JP Morgan keeps at overweight with a 330p target. Royal Dutch Shell: RBC reiterates outperform with a target price of 2000p and JP Morgan stays atneutral with a target price of 1630p. National

19 May 2016 08:30

BROKER RATINGS SUMMARY: Goldman Sachs Upgrades BT To Conviction Buy

18 May 2016 08:31

BROKER RATINGS SUMMARY: Goldman Upgrades Booker, Panmure Cuts Meggitt

17 May 2016 09:40

WINNERS & LOSERS SUMMARY: Taylor Wimpey Pleases With Payout Plan

17 May 2016 07:56

Revenue jump boosts BTG full-year profits

(ShareCast News) - Healthcare company BTG more than doubled full year pre-tax profits to £57.5m on the back of a 22% jump in revenues to £447.5m. The company said expected revenue for fiscal 2017 to be in the range of £485m-£515m, with selling general and administrative costs to be £160m-£170m and r

17 May 2016 06:57

TOP NEWS: BTG Doubles Annual Profit On Significant Revenue Rise

10 May 2016 15:10

Earnings, Trading Statements Calendar - Week Ahead

6 May 2016 09:23

BTG buys Galil Medical for inital £58.3

(ShareCast News) - Specialist healthcare company BTG said it was buying Galil Medical, a leading provider of cryoablation products for the treatment and palliative care of kidney and other cancers, for an initial £58.3m. BTG said it would also pay up to £17.6m in future regulatory and commercial mil

6 May 2016 08:10

BTG Acquires US-Based Cryoablation Systems Maker Galil Medical

5 Apr 2016 07:41

BTG exudes confidence ahead of final reuslts

(ShareCast News) - Specialist healthcare company BTG was confident ahead of its final results on Tuesday, claiming reported group revenue for the year to 31 March was expected to be at the upper end of its guidance range of £410m-£440m, boosted by currency tailwinds. The growth at the FTSE 250 compa

5 Apr 2016 06:39

BTG Revenue To Hit Upper End Of Guidance Amid Solid Sales Growth

4 Apr 2016 05:23

BTG To Initiate Target Study To Evaluate Dosimetry For HCC Patients

5 Jan 2016 09:43

BROKER RATINGS SUMMARY: S&P CapIQ Cuts Next To Buy From Strong Buy

15 Dec 2015 17:05

LONDON MARKET CLOSE: Oil Recovers As US Inflation Supports Fed Hike

15 Dec 2015 15:24

FTSE 250 movers: Broker notes spur on big movers

(ShareCast News) - The FTSE 250 looks to finish the day in the green, with the second-tier market up 228.85 point (1.36%) to 17,001.42 mid-afternoon Tuesday. Circassia Pharmaceuticals rose to the top of the ranks after RBC Capital Markets initiated coverage at 'top pick' for the company. "With intr

Latest Share Chat

BTG Share News (BTG)

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

BTG's emphysema treatment struck down by FDA

Login to your account

Quickpicks are a member only feature

Login to your account